EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Brain p3‐Alcβ peptide restores neuronal viability impaired by Alzheimer's amyloid β‐peptide

Saori Hata, Haruka Saito, Takeharu Kakiuchi, Dai Fukumoto, Shigeyuki Yamamoto iD, Kensaku Kasuga iD, Ayano Kimura, Koichi Moteki, Ruriko Abe, Shungo Adachi, Shoich Kinoshita, Kumiko Yoshizawa-Kumagaye und 14 weitere

EMBO Molecular Medicine · 2023

DOI: 10.15252/emmm.202217052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Saori Hata und 25 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Naito Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We propose a new therapeutic strategy for Alzheimer's disease (AD). Brain peptide p3‐Alcβ37 is generated from the neuronal protein alcadein β through cleavage of γ‐secretase, similar to the generation of amyloid β (Aβ) derived from Aβ‐protein precursor/APP. Neurotoxicity by Aβ oligomers (Aβo) is the prime cause prior to the loss of brain function in AD. We found that p3‐Alcβ37 and its shorter peptide p3‐Alcβ9‐19 enhanced the mitochondrial activity of neurons and protected neurons against Aβo‐induced toxicity. This is due to the suppression of the Aβo‐mediated excessive Ca 2+ influx into neurons by p3‐Alcβ. Successful transfer of p3‐Alcβ9‐19 into the brain following peripheral administration improved the mitochondrial viability in the brain of AD mice model, in which the mitochondrial activity is attenuated by increasing the neurotoxic human Aβ42 burden, as revealed through brain PET imaging to monitor mitochondrial function. Because mitochondrial dysfunction is common in the brain of AD patients alongside increased Aβ and reduced p3‐Alcβ37 levels, the administration of p3‐Alcβ9‐19 may be a promising treatment for restoring, protecting, and promoting brain functions in patients with AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesAlzheimer DiseaseMiceAnimalsHumansAmyloid beta-Protein PrecursorBrainNeuronsAmyloid Precursor Protein SecretasesIntercellular Signaling Peptides and Proteins

Stichwörter der Autor:innen

AD therapyAlzheimer's disease (AD)PET imagingalcadeinmitochondria

Substanzen

Amyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid Precursor Protein Secretasespeptide P3Intercellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan.
  • Advanced Prevention and Research Laboratory for Dementia, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Japan.
  • Molecular Genetics, Niigata University Brain Research Institute, Nigata, Japan.
  • Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan.

ORCID-Profile: Shigeyuki Yamamoto, Kensaku Kasuga, Takashi Saito, Takaomi C Saido, Tohru Yamamoto, Hiroyuki Ohba, Norihiro Harada, Takeshi Ikeuchi, Hideo Tsukada, Toshiharu Suzuki

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • Naito Foundation

Zitieren

APA

Hata, S., Saito, H., Kakiuchi, T., Fukumoto, D., Yamamoto, S., Kasuga, K., Kimura, A., Moteki, K., Abe, R., Adachi, S., Kinoshita, S., Yoshizawa-Kumagaye, K., Nishio, H., Saito, T., Saido, T. C., Yamamoto, T., Nishimura, M., Taru, H., Sobu, Y., …, & Suzuki, T. (2023). Brain p3‐Alcβ peptide restores neuronal viability impaired by Alzheimer's amyloid β‐peptide. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202217052

Vancouver

Hata S, Saito H, Kakiuchi T, Fukumoto D, Yamamoto S, Kasuga K, et al. Brain p3‐Alcβ peptide restores neuronal viability impaired by Alzheimer's amyloid β‐peptide. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202217052

BibTeX
@article{Hata2023,
  author = {Hata, Saori and Saito, Haruka and Kakiuchi, Takeharu and Fukumoto, Dai and Yamamoto, Shigeyuki and Kasuga, Kensaku and Kimura, Ayano and Moteki, Koichi and Abe, Ruriko and Adachi, Shungo and Kinoshita, Shoich and Yoshizawa-Kumagaye, Kumiko and Nishio, Hideki and Saito, Takashi and Saido, Takaomi C and Yamamoto, Tohru and Nishimura, Masaki and Taru, Hidenori and Sobu, Yuriko and Ohba, Hiroyuki and Nishiyama, Shingo and Harada, Norihiro and Ikeuchi, Takeshi and Tsukada, Hideo and Ouchi, Yasuomi and Suzuki, Toshiharu},
  title = {Brain p3‐Alcβ peptide restores neuronal viability impaired by Alzheimer's amyloid β‐peptide},
  journal = {EMBO Molecular Medicine},
  year = {2023},
  doi = {10.15252/emmm.202217052}
}
Kostenlos starten →